Matt Gline, Roivant CEO (courtesy Roivant)

Roivan­t's JAK/TYK2 in­hibitor fails PhII lu­pus study

Roivant re­port­ed Mon­day morn­ing that a pro­gram li­censed from Pfiz­er failed a Phase II lu­pus tri­al and that it would end de­vel­op­ment in the con­di­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.